Overview: Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors Introduction Classes of PI3Ks PI3K Isoforms Role of PI3K δ in Normal and Disease States Future Perspectives Pipeline Therapeutics (Active Products) Comparative Analysis Late Stage Products (Phase III) Comparative Analysis Leniolisib: Novartis Product Description Research and Development (The list continues) Mid-Stage Products (Phase II) Comparative Analysis Early Stage Products (Phase I) Comparative Analysis Pre-clinical and Unknown Stage Products Comparative Analysis Dormant Products Comparative Analysis Therapeutic Assessment: Active Products Assessment by Route of Administration Assessment by Stage and Route of Administration

Table 1: Total Products for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors Table 2: Late Stage Products (Phase III) Table 3: Mid Stage Products (Phase II) Table 4: Early Stage Products (Phase I) Table 5: Pre-clinical Stage Products Table 6: Dormant Products Table 7: Assessment by Route of Administration Table 8: Assessment by Stage and Route of Administration Figure 1: Action of all the forms of PI3K signaling pathway inhibitors Figure 2: Total Products for Phosphoinositide 3-Kinase Delta (PI3K Delta) Inhibitors Figure 3: Late Stage Products (Phase III) Figure 4: Mid Stage Products (Phase II) Figure 5: Early Stage Products (Phase I) Figure 6: Pre-clinical Stage Products Figure 7: Dormant Products Figure 8: Assessment by Route of Administration Figure 9: Assessment by Stage and Route of Administration

UCB Acerta Pharma Exelixix GlaxoSmithKline Hutchison MediPharma Incyte Incyte Corporation Johnson & Johnson MEI Pharma Merck Novartis Rhizen Pharmaceuticals SignalRx Pharmaceuticals TargeGen TG Therapeutics Verastem Xcovery